ReviewJournal of food and drug analysis2026
Metabolomics in precision medicine: Application and prospect in cancer research.
Review in Journal of food and drug analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolomics is the most recent and final discipline among the post-genomic, multiomics fields. It encompasses key technologies in systems biology, providing an overview of low-molecular-weight metabolites while examining disturbances to offer pathophysiological explanations. The two key analytical tools in metabolomics are nuclear magnetic resonance spectroscopy and mass spectrometry, which includes gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Metabolomic research relies on a three-stage data generation process: the first stage involves precise analytical chemistry to produce data; the second stage employs multivariate statistical analysis; and the last stage uses big data as a reference for comparison to establish biochemical, metabolic, and pathophysiological correlations, thereby providing possible interpretations. The initiative of precision medicine starts with cancer as the first disease target. This review discusses and illustrates the application of metabolomics in precision medicine, choosing two types of cancer as example. Warburg effect and metabolic reprogramming are particularly discussed. By providing global, top-down, and less biased information, metabolomics enables precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.